

Juan Luis Tamargo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6214098/publications.pdf>

Version: 2024-02-01

332
papers

80,693
citations

8159

76
h-index

407

277
g-index

373
all docs

373
docs citations

373
times ranked

60085
citing authors

#	ARTICLE	IF	CITATIONS
1	Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 187-210.	1.4	10
2	The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 85-99.	1.4	23
3	Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome. <i>Cardiovascular Research</i> , 2022, 118, 1046-1060.	1.8	15
4	Editorial commentary: Adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 234-236.	2.3	3
5	Sex-related differences in the pharmacological treatment of heart failure. , 2022, 229, 107891.		14
6	Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 100-103.	1.4	4
7	Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina. <i>Future Cardiology</i> , 2022, 18, 235-251.	0.5	8
8	Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity. <i>Drug Safety</i> , 2022, 45, 101-126.	1.4	6
9	An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps. <i>Cardiovascular Drugs and Therapy</i> , 2022, , 1.	1.3	3
10	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 453-459.	1.4	5
11	Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 51-58.	0.4	5
12	Estudio farmacodinámico del policomprimido cardiovascular: ¿existe algún tipo de interacción entre los monocomponentes?. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 51-58.	0.6	9
13	Cardiovascular Medications. , 2021, , 597-642.		1
14	The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1319-1341.	0.9	0
15	Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 557-567.	1.4	10
16	Estratificación, monitorización y control del riesgo cardiovascular en pacientes con cáncer. Documento de consenso de SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AECC y AECC. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 438-448.	0.6	22
17	Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AECC, and AECC. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 438-448.	0.4	6
18	Does anticoagulation reduce mortality in patients with atrial fibrillation who later developed a COVID-19 infection?. <i>International Journal of Cardiology</i> , 2021, 331, 340-341.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	1.4	6
20	Fluoroquinolone use and valvular heart disease: is the jury still out?. European Heart Journal, 2021, 42, 2909-2911.	1.0	1
21	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. International Journal of Cardiology, 2021, 337, 1-8.	0.8	6
22	ISCHEMIA Trial: Key Questions and Answers. European Cardiology Review, 2021, 16, e34.	0.7	2
23	Is It Safe (and When) to Stop Oral Anticoagulation After Ablation for Atrial fibrillation? (Do We Have) Tj ETQq1 1 0.784314 rgBT /Ove	1.3	1
24	Factors associated with poor prognosis in patients with atrial fibrillation: An emergency department perspective the EMERG-AF study. American Journal of Emergency Medicine, 2021, 50, 270-277.	0.7	3
25	Association between acute heart failure and major cardiovascular events in atrial fibrillation patients presenting at the emergency department: an EMERG-AF ancillary study. European Journal of Emergency Medicine, 2021, 28, 210-217.	0.5	0
26	Zfhx3 Transcription Factor Represses the Expression of SCN5A Gene and Decreases Sodium Current Density (INa). International Journal of Molecular Sciences, 2021, 22, 13031.	1.8	9
27	Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 104-114.	1.4	25
28	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 86-93.	1.4	27
29	Low quality of some generic cardiovascular medicinal products represents a matter for growing concern. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 176-187.	1.4	3
30	After a long time, the new ESC Guidelines for the management of patients with supraventricular tachycardia are here. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 3-5.	1.4	1
31	The p.P888L SAP97 polymorphism increases the transient outward current (Ito,f) and abbreviates the action potential duration and the QT interval. Scientific Reports, 2020, 10, 10707.	1.6	7
32	Cardiovascular pharmacotherapy in older people: challenges posed by cardiovascular drug prescription in the elderly. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 277-279.	1.4	7
33	Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs. European Heart Journal, 2020, 41, 2067-2069.	1.0	13
34	Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 425-437.	1.0	1
35	Selecting emergency therapy for patients with pre-eclampsia. Expert Opinion on Pharmacotherapy, 2020, 21, 1119-1122.	0.9	0
36	Treatment of Coronavirus Disease 2019: Shooting in the Dark. European Cardiology Review, 2020, 15, e59.	0.7	2

#	ARTICLE	IF	CITATIONS
37	Class III Antiarrhythmic Drugs. , 2020, , 107-180.		0
38	Comparison of Noninvasive Cardiac Test Strategies for Newly Diagnosed Chagas Disease in a Non-Endemic Zone. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1480-1486.	0.6	1
39	Sodiumâ€“glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments. European Cardiology Review, 2019, 14, 23-32.	0.7	44
40	Happy 50th anniversary of amiodarone (1969â€“2019). International Journal of Cardiology, 2019, 293, 115-116.	0.8	2
41	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 171-180.	1.4	46
42	Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. Hypertension, 2019, 74, 130-136.	1.3	12
43	Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 226-236.	1.4	31
44	Digenic Heterozigosity in SCN5A and CACNA1C Explains the Variable Expressivity of the Long QT Phenotype in a Spanish Family. Revista Espanola De Cardiologia (English Ed), 2019, 72, 324-332.	0.4	4
45	Pharmacotherapy for hypertension in pregnant patients: special considerations. Expert Opinion on Pharmacotherapy, 2019, 20, 963-982.	0.9	7
46	New drugs in preclinical and early stage clinical development in the treatment of heart failure. Expert Opinion on Investigational Drugs, 2019, 28, 51-71.	1.9	15
47	Cardiovascular Effects of Flavonoids. Current Medicinal Chemistry, 2019, 26, 6991-7034.	1.2	41
48	New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors. Cardiovascular Drugs and Therapy, 2018, 32, 99-119.	1.3	22
49	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal, 2018, 39, 2274-2281.	1.0	16
50	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 180-188.	1.4	113
51	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39, 763-816.	1.0	2,305
52	Pharmacological Bases of Antiarrhythmic Therapy. , 2018, , 513-524.		2
53	Editor's Choice â€“ 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery, 2018, 55, 305-368.	0.8	734
54	New potassium binders reduce the risk of hyperkalaemia in patients treated with reninâ€“angiotensinâ€“aldosterone system inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 193-194.	1.4	6

#	ARTICLE	IF	CITATIONS
55	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>European Heart Journal</i> , 2018, 39, 3165-3241.	1.0	1,396
56	Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 230-236.	1.4	39
57	Brugada syndrome traffickingâ€“defective Nav1.5 channels can trap cardiac Kir2.1/2.2 channels. <i>JCI Insight</i> , 2018, 3, .	2.3	37
58	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical managementâ€“a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehv676.	1.0	48
59	Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes. <i>International Journal of Cardiology</i> , 2017, 233, 1-11.	0.8	8
60	Comprehensive efforts to increase adherence to statin therapy. <i>European Heart Journal</i> , 2017, 38, ehw628.	1.0	40
61	Benefits of Emergency Departmentsâ€™ Contribution to Stroke Prophylaxis in Atrial Fibrillation. <i>Stroke</i> , 2017, 48, 1344-1352.	1.0	20
62	Future drug discovery in renin-angiotensin-aldosterone system intervention. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-22.	2.5	26
63	Reninâ€“angiotensin system blockade: Finerenone. <i>Nephrologie Et Therapeutique</i> , 2017, 13, S47-S53.	0.2	17
64	Aldosterone a Relevant Factor in the Beginning and Evolution of Arterial Hypertension. <i>American Journal of Hypertension</i> , 2017, 30, 468-469.	1.0	5
65	Tbx20 controls the expression of the <i>KCNH2</i> gene and of hERG channels. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E416-E425.	3.3	38
66	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42.	2.9	920
67	Kir2.1-Nav1.5 Channel Complexes Are Differently Regulated than Kir2.1 and Nav1.5 Channels Alone. <i>Frontiers in Physiology</i> , 2017, 8, 903.	1.3	35
68	EdoxabÃ¡n. Propiedades farmacocinÃ©ticas y farmacodinÃ¡micas. <i>Revista Espanola De Cardiologia Suplementos</i> , 2016, 16, 60-66.	0.2	2
69	Management of stable angina: A commentary on the European Society of Cardiology guidelines. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1401-1412.	0.8	30
70	Role of UCP2 in the protective effects of PPAR γ activation on lipopolysaccharide-induced endothelial dysfunction. <i>Biochemical Pharmacology</i> , 2016, 110-111, 25-36.	2.0	25
71	Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 200-205.	1.4	30
72	Vascular and Central Activation of Peroxisome Proliferator-Activated Receptor- α Attenuates Angiotensin II-Induced Hypertension: Role of RGS-5. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 151-163.	1.3	16

#	ARTICLE	IF	CITATIONS
73	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	0.6	754
74	Investigational calcium channel blockers for the treatment of hypertension. Expert Opinion on Investigational Drugs, 2016, 25, 1295-1309.	1.9	15
75	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	1.0	5,689
76	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	0.7	3,523
77	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal, 2016, 37, 2768-2801.	1.0	1,996
78	Cardiac electrical defects in progeroid mice and Hutchinsonâ€™s Gilford progeria syndrome patients with nuclear lamina alterations. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7250-E7259.	3.3	39
79	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 108-118.	1.4	35
80	Pitx2c increases in atrial myocytes from chronic atrial fibrillation patients enhancing I_{Ks} and decreasing $I_{Ca,L}$. Cardiovascular Research, 2016, 109, 431-441.	1.8	59
81	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal, 2016, 37, 1015-1023.	1.0	109
82	Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence. Diabetes and Vascular Disease Research, 2016, 13, 98-112.	0.9	10
83	Nav1.5 N-terminal domain binding to β 1-syntrophin increases membrane density of human Kir2.1, Kir2.2 and Nav1.5 channels. Cardiovascular Research, 2016, 110, 279-290.	1.8	77
84	An update on atrial fibrillation in 2014: From pathophysiology to treatment. International Journal of Cardiology, 2016, 203, 22-29.	0.8	56
85	Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: Figure A1. European Heart Journal, 2015, 36, 2677-2680.	1.0	131
86	New Antianginal Drugs Still Not Available for Clinical Use. , 2015, , 189-234.		0
87	The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. International Journal of Cardiology, 2015, 201, S15-S23.	0.8	32
88	Cancer Chemotherapy and Cardiac Arrhythmias: A Review. Drug Safety, 2015, 38, 129-152.	1.4	118
89	Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. European Journal of Clinical Pharmacology, 2015, 71, 549-567.	0.8	166
90	Unresolved issues in the management of chronic stable angina. International Journal of Cardiology, 2015, 201, 200-207.	0.8	27

#	ARTICLE	IF	CITATIONS
91	The Renin-angiotensin System and Bone. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2015, 13, 125-148.	1.3	14
92	2015 ESC Guidelines for the management of infective endocarditis. <i>European Heart Journal</i> , 2015, 36, 3075-3128.	1.0	3,902
93	Pharmacologic Bases of Antiarrhythmic Therapy. , 2014, , 529-540.		1
94	Structural basis of drugs that increase cardiac inward rectifier Kir2.1 currents. <i>Cardiovascular Research</i> , 2014, 104, 337-346.	1.8	24
95	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. <i>European Heart Journal</i> , 2014, 35, 2383-2431.	1.0	1,253
96	Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 527-547.	0.9	62
97	Chronic Atrial Fibrillation Increases MicroRNA-21 in Human Atrial Myocytes Decreasing L-Type Calcium Current. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 861-868.	2.1	83
98	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2733-2779.	1.0	3,469
99	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	1.0	4,141
100	2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. <i>European Heart Journal</i> , 2014, 35, 2873-2926.	1.0	3,549
101	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. <i>European Heart Journal</i> , 2014, 35, 3155-3179.	1.0	490
102	Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 605-621.	0.9	51
103	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	1.0	2,591
104	Comparison of Agents That Affect Aldosterone Action. <i>Seminars in Nephrology</i> , 2014, 34, 285-306.	0.6	28
105	New Antihypertensive Drugs Under Development. <i>Current Medicinal Chemistry</i> , 2014, 22, 305-342.	1.2	21
106	New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors -- hype or hope?. <i>Discovery Medicine</i> , 2014, 18, 249-54.	0.5	8
107	Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011) Tj ETQq1 1 0.784314 rgBT /Overlock 1.2 222		
108	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758

#	ARTICLE	IF	CITATIONS
109	p.D1690N Nav1.5 rescues p.G1748D mutation gating defects in a compound heterozygous Brugada syndrome patient. <i>Heart Rhythm</i> , 2013, 10, 264-272.	0.3	42
110	Propafenone blocks human cardiac Kir2.x channels by decreasing the negative electrostatic charge in the cytoplasmic pore. <i>Biochemical Pharmacology</i> , 2013, 86, 267-278.	2.0	27
111	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	1.0	5,681
112	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	1.0	3,915
113	Chronic atrial fibrillation up-regulates β_1 -Adrenoceptors affecting repolarizing currents and action potential duration. <i>Cardiovascular Research</i> , 2013, 97, 379-388.	1.8	57
114	Effects of peroxisome proliferator-activated receptor- β activation in endothelin-dependent hypertension. <i>Cardiovascular Research</i> , 2013, 99, 622-631.	1.8	23
115	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2013, 34, 2281-2329.	1.0	2,176
116	Functional Characterization of a Novel Frameshift Mutation in the C-terminus of the Nav1.5 Channel Underlying a Brugada Syndrome with Variable Expression in a Spanish Family. <i>PLoS ONE</i> , 2013, 8, e81493.	1.1	18
117	Platelet Content of Nitric Oxide Synthase 3 Phosphorylated At Serine1177 Is Associated with the Functional Response of Platelets to Aspirin. <i>PLoS ONE</i> , 2013, 8, e82574.	1.1	10
118	TGF β 3 mutations cause arrhythmogenic right ventricular dysplasia type 1 and open the door to understanding the biological role of TGF β 3 (where there's a will, there's a way): EXPERT'S PERSPECTIVE. <i>Cardiovascular Research</i> , 2012, 96, 188-190.	1.8	6
119	Activation of peroxisome proliferator-activated receptor- β / δ (PPAR β / δ) prevents endothelial dysfunction in type 1 diabetic rats. <i>Free Radical Biology and Medicine</i> , 2012, 53, 730-741.	1.3	57
120	Safety of Flecainide. <i>Drug Safety</i> , 2012, 35, 273-289.	1.4	29
121	Drug-induced atrial fibrillation. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 615-634.	1.0	22
122	Glucuronidated Quercetin Lowers Blood Pressure in Spontaneously Hypertensive Rats via Deconjugation. <i>PLoS ONE</i> , 2012, 7, e32673.	1.1	104
123	Plasma desmoplakin I biomarker of vascular recurrence after ischemic stroke. <i>Journal of Neurochemistry</i> , 2012, 121, 314-325.	2.1	12
124	Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. <i>Free Radical Biology and Medicine</i> , 2012, 52, 70-79.	1.3	154
125	Drug-induced atrial fibrillation: does it matter?. <i>Discovery Medicine</i> , 2012, 14, 295-9.	0.5	11
126	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on) Tj ETQq0,0,0 rgBT /Overlock 1	0.3	114

#	ARTICLE	IF	CITATIONS
127	Functional effects of a missense mutation in HERG associated with type 2 long QT syndrome. Heart Rhythm, 2011, 8, 463-470.	0.3	10
128	2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 57, e101-e198.	1.2	756
129	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq1 1 0.784314 rgBT /O	1.2	262
130	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq0 0 0 rgBT /Overlock 10	0.3	114
131	Novel therapeutic targets for the treatment of heart failure. Nature Reviews Drug Discovery, 2011, 10, 536-555.	21.5	125
132	Effects of khellin on contractile responses and $^{45}\text{Ca}^{2+}$ movements in rat isolated aorta. Journal of Pharmacy and Pharmacology, 2011, 43, 46-48.	1.2	17
133	A comparison of the effects of oxodipine and nifedipine on rat vas deferens. Journal of Pharmacy and Pharmacology, 2011, 40, 657-659.	1.2	2
134	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on) Tj ETQq0 0 0 rgBT /Overlock 10	1.6	406
135	Proteomic changes related to "bewildered" circulating platelets in the acute coronary syndrome. Proteomics, 2011, 11, 3335-3348.	1.3	40
136	Antihypertensive Effects of Peroxisome Proliferator-Activated Receptor- β Activation in Spontaneously Hypertensive Rats. Hypertension, 2011, 58, 733-743.	1.3	80
137	<i>PITX2</i> Insufficiency Leads to Atrial Electrical and Structural Remodeling Linked to Arrhythmogenesis. Circulation: Cardiovascular Genetics, 2011, 4, 269-279.	5.1	221
138	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq0 0 0 rgBT /Overlock 10	1.6	618
139	2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2011, 123, e269-367.	1.6	747
140	Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace, 2011, 13, 161-173.	0.7	140
141	Red wine polyphenols prevent endothelial dysfunction induced by endothelin-1 in rat aorta: role of NADPH oxidase. Clinical Science, 2011, 120, 321-333.	1.8	38
142	Ranolazine: an antianginal drug with antiarrhythmic properties. Expert Review of Cardiovascular Therapy, 2011, 9, 815-827.	0.6	10
143	Dronedarone. Drugs of Today, 2011, 47, 109.	0.7	5
144	New therapeutic targets for the development of positive inotropic agents. Discovery Medicine, 2011, 12, 381-92.	0.5	10

#	ARTICLE	IF	CITATIONS
145	New Investigational Drugs for the Management of Acute Heart Failure Syndromes. <i>Current Medicinal Chemistry</i> , 2010, 17, 363-390.	1.2	13
146	Old and New Molecular Mechanisms Associated with Platelet Resistance to Antithrombotics. <i>Pharmaceutical Research</i> , 2010, 27, 2365-2373.	1.7	17
147	Lack of beneficial metabolic effects of quercetin in adult spontaneously hypertensive rats. <i>European Journal of Pharmacology</i> , 2010, 627, 242-250.	1.7	30
148	Comparative Expression of Proteins in Left and Right Atrial Appendages From Patients With Mitral Valve Disease at Sinus Rhythm and Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2010, 21, 859-868.	0.8	28
149	The Impact of New and Emerging Clinical Data on Treatment Strategies for Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2010, 21, 946-958.	0.8	25
150	Flecainide increases Kir2.1 currents by interacting with cysteine 311, decreasing the polyamine-induced rectification. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15631-15636.	3.3	75
151	Cardiac electrophysiological effects of nitric oxide. <i>Cardiovascular Research</i> , 2010, 87, 593-600.	1.8	86
152	Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner. <i>Cardiovascular Research</i> , 2010, 85, 56-67.	1.8	48
153	In Humans, Chronic Atrial Fibrillation Decreases the Transient Outward Current and Ultrarapid Component of the Delayed Rectifier Current Differentially on Each Atria and Increases the Slow Component of the Delayed Rectifier Current in Both. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2346-2354.	1.2	152
154	Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 201-210.	0.9	30
155	Vascular superoxide production by endothelin-1 requires Src non-receptor protein tyrosine kinase and MAPK activation. <i>Atherosclerosis</i> , 2010, 212, 78-85.	0.4	29
156	Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 1039-47.	2.3	13
157	Investigational Positive Inotropic Agents for Acute Heart Failure. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2009, 9, 193-205.	0.2	17
158	I_{Kur} /Kv1.5 channel blockers for the treatment of atrial fibrillation. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 399-416.	1.9	69
159	Nitric Oxide Increases Cardiac I_{K1} by Nitrosylation of Cysteine 76 of Kir2.1 Channels. <i>Circulation Research</i> , 2009, 105, 383-392.	2.0	61
160	Vagal Stimulation and Atrial Electrical Remodeling. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 729-732.	0.4	1
161	Omecamtiv mecarbil cardiac myosin activator treatment of heart failure. <i>Drugs of the Future</i> , 2009, 34, 950.	0.0	1
162	Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1300-1312.	0.8	25

#	ARTICLE	IF	CITATIONS
163	Effects of MiRP1 and DPP6 β subunits on the blockade induced by flecainide of $K_{v4.3}/K_{ChIP2}$ channels. <i>British Journal of Pharmacology</i> , 2008, 154, 774-786.	2.7	23
164	The HERACLES Cardiovascular Network. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 66-75.	0.4	1
165	Nitric oxide inhibits $K_{v4.3}$ and human cardiac transient outward potassium current (Ito1). <i>Cardiovascular Research</i> , 2008, 80, 375-384.	1.8	41
166	The dietary flavonoid quercetin activates BKCa currents in coronary arteries via production of H ₂ O ₂ . Role in vasodilatation. <i>Cardiovascular Research</i> , 2007, 73, 424-431.	1.8	77
167	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal Supplements</i> , 2007, 9, C3-C74.	0.0	40
168	2007 Guidelines for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1105-1187.	0.3	4,778
169	Role of Protein Kinase C δ and Its Adaptor Protein p62 in Voltage-Gated Potassium Channel Modulation in Pulmonary Arteries. <i>Molecular Pharmacology</i> , 2007, 72, 1301-1309.	1.0	19
170	Quercetin and Isorhamnetin Prevent Endothelial Dysfunction, Superoxide Production, and Overexpression of p47phox Induced by Angiotensin II in Rat Aorta. <i>Journal of Nutrition</i> , 2007, 137, 910-915.	1.3	98
171	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 30</i>	1.0	55
172	Corrigendum to 'ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30</i>	0.7	10
173	Effects of atorvastatin and simvastatin on atrial plateau currents. <i>Journal of Molecular and Cellular Cardiology</i> , 2007, 42, 931-945.	0.9	45
174	Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. , 2007, 114, 107-126.		40
175	Genetically engineered mice as a model for studying cardiac arrhythmias. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 22.	3.0	16
176	Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. <i>European Heart Journal</i> , 2006, 27, 1341-1381.	1.0	1,192
177	The safety of digoxin as a pharmacological treatment of atrial fibrillation. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 453-467.	1.0	16
178	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Journal of the American College of Cardiology</i> , 2006, 48, e247-e346.	1.2	1,280
179	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1064-1108.	1.2	154
180	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2006, 48, 854-906.	1.2	1,044

#	ARTICLE	IF	CITATIONS
181	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2006, 48, e149-e246.	1.2	312
182	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70	0.7	661
183	Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace, 2006, 8, 651-745. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2006, 28, 88-136.	1.0	1,144
184	Proteomic Study of Plasma from Moderate Hypercholesterolemic Patients. Journal of Proteome Research, 2006, 5, 2301-2308.	1.8	40
185	Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. Journal of Hypertension, 2006, 24, 75-84.	0.3	253
186	Role of Reactive Oxygen Species in Kv Channel Inhibition and Vasoconstriction Induced by TP Receptor Activation in Rat Pulmonary Arteries. Annals of the New York Academy of Sciences, 2006, 1091, 41-51.	1.8	57
187	Increased NADPH oxidase activity mediates spontaneous aortic tone in genetically hypertensive rats. European Journal of Pharmacology, 2006, 544, 97-103.	1.7	55
188	Farmacología de los Ácidos grasos omega-3. Revista Espanola De Cardiologia Suplementos, 2006, 6, 3D-19D.	0.2	1
189	Mecanismo de acción de la eplerenona. Revista Espanola De Cardiologia Suplementos, 2006, 6, 31B-47B.	0.2	1
190	Características farmacológicas de los ARA-II. ¿Son todos iguales?. Revista Espanola De Cardiologia Suplementos, 2006, 6, 10C-24C.	0.2	2
191	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 70	1.0	454
192	with the European Heart Rhythm Associat. European Heart Journal, 2006, 27, 2099-2140. Relaxant Effects of the Soluble Guanylate Cyclase Activator and NO Sensitizer YC-1 in Piglet Pulmonary Arteries. Neonatology, 2006, 90, 66-72.	0.9	4
193	Nitric oxide blocks hKv1.5 channels by S-nitrosylation and by a cyclic GMP-dependent mechanism. Cardiovascular Research, 2006, 72, 80-89.	1.8	74
194	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2006, 114, e385-484.	1.6	1,031
195	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary. Circulation, 2006, 114, 700-752.	1.6	294
196	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70	0.7	516
197	Rhythm Association and the Heart R. Europace, 2006, 8, 746-837. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary. European Heart Journal, 2006, 27, 1979-2030.	1.0	612
198	Association of 14-3-3 Proteins to β 1-Adrenergic Receptors Modulates Kv11.1 K ⁺ Channel Activity in Recombinant Systems. Molecular Biology of the Cell, 2006, 17, 4666-4674.	0.9	24

#	ARTICLE	IF	CITATIONS
199	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. <i>Circulation</i> , 2006, 114, e257-354.	1.6	2,120
200	Serotonin Inhibits Voltage-Gated K ⁺ Currents in Pulmonary Artery Smooth Muscle Cells. <i>Circulation Research</i> , 2006, 98, 931-938.	2.0	170
201	New insights in the pharmacological therapy of arterial hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2005, 14, 423-427.	1.0	21
202	Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1+minK channels. <i>British Journal of Pharmacology</i> , 2005, 146, 146-161.	2.7	26
203	Postnatal maturational shift from PKC β and voltage-gated K channels to RhoA/Rho kinase in pulmonary vasoconstriction. <i>Cardiovascular Research</i> , 2005, 66, 84-93.	1.8	35
204	Soluble guanylyl cyclase during postnatal porcine pulmonary maturation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2005, 288, L125-L130.	1.3	22
205	Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 155-161.	4.0	36
206	Postnatal Maturation of Phosphodiesterase 5 (PDE5) in Piglet Pulmonary Arteries: Activity, Expression, Effects of PDE5 Inhibitors, and Role of the Nitric Oxide/Cyclic GMP Pathway. <i>Pediatric Research</i> , 2004, 56, 563-570.	1.1	29
207	Pharmacological Approaches in the Treatment of Atrial Fibrillation. <i>Current Medicinal Chemistry</i> , 2004, 11, 13-28.	1.2	23
208	Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease The Task Force on ACE-inhibitors of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1454-1470.	1.0	249
209	Nitric Oxide (NO) Scavenging and NO Protecting Effects of Quercetin and Their Biological Significance in Vascular Smooth Muscle. <i>Molecular Pharmacology</i> , 2004, 65, 851-859.	1.0	89
210	Expert consensus document on β -adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1341-1362.	1.0	465
211	Blood Pressure Control and Physician Management of Hypertension in Hospital Hypertension Units in Spain. <i>Hypertension</i> , 2004, 43, 1338-1344.	1.3	183
212	Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations. <i>Cardiovascular Research</i> , 2004, 64, 457-466.	1.8	28
213	Interaction of angiotensin II with the angiotensin type 2 receptor inhibits the cardiac transient outward potassium current. <i>Cardiovascular Research</i> , 2004, 62, 86-95.	1.8	40
214	Pharmacology of cardiac potassium channels. <i>Cardiovascular Research</i> , 2004, 62, 9-33.	1.8	398
215	Bases y evidencias clínicas de los efectos de los nuevos tratamientos farmacológicos en la insuficiencia cardíaca. <i>Revista Espanola De Cardiologia</i> , 2004, 57, 447-464.	0.6	12
216	Rationale and Clinical Evidence for the Effects of New Pharmacological Treatments for Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2004, 57, 447-464.	0.4	2

#	ARTICLE	IF	CITATIONS
217	Effects of flecainide and quinidine on Kv4.2 currents: voltage dependence and role of S6 valines. <i>British Journal of Pharmacology</i> , 2003, 138, 1475-1484.	2.7	24
218	Cytosolic Ca ²⁺ and Phosphoinositide Hydrolysis Linked to Constitutively Active $\hat{I}\pm 1d$ -Adrenoceptors in Vascular Smooth Muscle. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 1006-1014.	1.3	16
219	Effects of Irbesartan on Cloned Potassium Channels Involved in Human Cardiac Repolarization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 862-873.	1.3	66
220	Spironolactone and Its Main Metabolite, Canrenoic Acid, Block Human Ether-a-Go-go-Related Gene Channels. <i>Circulation</i> , 2003, 107, 889-895.	1.6	65
221	Thromboxane A ₂ -Induced Inhibition of Voltage-Gated K ⁺ Channels and Pulmonary Vasoconstriction. <i>Circulation Research</i> , 2003, 93, 656-663.	2.0	140
222	Effects of the Flavonoid Quercetin and its Methylated Metabolite Isorhamnetin in Isolated Arteries from Spontaneously Hypertensive Rats. <i>Planta Medica</i> , 2003, 69, 995-1000.	0.7	50
223	Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels. <i>Cardiovascular Research</i> , 2003, 57, 660-669.	1.8	25
224	Cardiovascular Effects of Isorhamnetin and Quercetin in Isolated Rat and Porcine Vascular Smooth Muscle and Isolated Rat Atria. <i>Planta Medica</i> , 2002, 68, 307-310.	0.7	54
225	Antihypertensive Efficacy and Tolerability of Lercanidipine in Daily Clinical Practice. The ELYPSE Study. <i>Blood Pressure</i> , 2002, 11, 95-100.	0.7	54
226	Assembly with the Kv ² 1.3 Subunit Modulates Drug Block of hKv1.5 Channels. <i>Molecular Pharmacology</i> , 2002, 62, 1456-1463.	1.0	38
227	Endothelium-Independent Vasodilator Effects of the Flavonoid Quercetin and Its Methylated Metabolites in Rat Conductance and Resistance Arteries. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 66-72.	1.3	170
228	Protective effects of the flavonoid quercetin in chronic nitric oxide deficient rats. <i>Journal of Hypertension</i> , 2002, 20, 1843-1854.	0.3	124
229	Hypertension magnitude and management in the elderly population of Spain. <i>Journal of Hypertension</i> , 2002, 20, 2157-2164.	0.3	217
230	Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5). <i>Cardiovascular Research</i> , 2002, 56, 104-117.	1.8	38
231	Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: stereoselective bupivacaine block. <i>British Journal of Pharmacology</i> , 2002, 137, 1269-1279.	2.7	46
232	Postnatal maturation in nitric oxide-induced pulmonary artery relaxation involving cyclooxygenase-1 activity. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2002, 283, L839-L848.	1.3	13
233	Direct Effects of Candesartan and Eprosartan on Human Cloned Potassium Channels Involved in Cardiac Repolarization. <i>Molecular Pharmacology</i> , 2001, 59, 825-836.	1.0	34
234	Effects of chronic quercetin treatment on hepatic oxidative status of spontaneously hypertensive rats. <i>Molecular and Cellular Biochemistry</i> , 2001, 221, 155-160.	1.4	74

#	ARTICLE	IF	CITATIONS
235	Mechanisms involved in SNP-induced relaxation and $[Ca^{2+}]_i$ reduction in piglet pulmonary and systemic arteries. <i>British Journal of Pharmacology</i> , 2001, 132, 959-967.	2.7	28
236	Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. <i>British Journal of Pharmacology</i> , 2001, 133, 117-124.	2.7	381
237	Nitric oxide- and nitric oxide donors-induced relaxation and its modulation by oxidative stress in piglet pulmonary arteries. <i>British Journal of Pharmacology</i> , 2001, 133, 615-624.	2.7	23
238	Flavonoids and cardiovascular diseases. <i>Studies in Natural Products Chemistry</i> , 2001, 25, 565-605.	0.8	14
239	Pulmonary Artery Vasoconstriction but not $[Ca^{2+}]_i$ Signal Stimulated by Thromboxane A2 Is Partially Resistant to NO. <i>Pediatric Research</i> , 2001, 50, 508-514.	1.1	8
240	Vasorelaxant Effects of the Bioflavonoid Chrysin in Isolated Rat Aorta. <i>Planta Medica</i> , 2001, 67, 567-569.	0.7	50
241	Drug-Induced Torsade de Pointes. From Molecular Biology to Bedside.. <i>The Japanese Journal of Pharmacology</i> , 2000, 83, 1-19.	1.2	102
242	Relaxant Effects of Carbon Monoxide Compared with Nitric Oxide in Pulmonary and Systemic Vessels of Newborn Piglets. <i>Pediatric Research</i> , 2000, 48, 546-553.	1.1	53
243	Losartan and Its Metabolite E3174 Modify Cardiac Delayed Rectifier K ⁺ Currents. <i>Circulation</i> , 2000, 101, 1199-1205.	1.6	71
244	Drug-Induced Torsade de Pointes: From Molecular Biology to Bedside. <i>The Japanese Journal of Pharmacology</i> , 2000, 83, 1-19.	1.2	15
245	Modulation of arterial $Na^{+}-K^{+}-ATPase$ -induced $[Ca^{2+}]_i$ reduction and relaxation by norepinephrine, ET-1, and PMA. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 276, H651-H657.	1.5	5
246	Functional expression of an inactivating potassium channel (Kv4.3) in a mammalian cell line. <i>Cardiovascular Research</i> , 1999, 41, 212-219.	1.8	35
247	Benzocaine enhances and inhibits the K ⁺ current through a human cardiac cloned channel (Kv1.5). <i>Cardiovascular Research</i> , 1999, 42, 510-520.	1.8	16
248	Effects of nicorandil as compared to mixtures of sodium nitroprusside and levromakalim in isolated rat aorta. <i>British Journal of Pharmacology</i> , 1999, 126, 1025-1033.	2.7	15
249	Involvement of thromboxane A2 in the endothelium-dependent contractions induced by myricetin in rat isolated aorta. <i>British Journal of Pharmacology</i> , 1999, 127, 1539-1544.	2.7	28
250	Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac Kv1.5 channels. <i>British Journal of Pharmacology</i> , 1999, 128, 1071-1081.	2.7	27
251	Vasodilator effects of sodium nitroprusside, levromakalim and their combination in isolated rat aorta. <i>British Journal of Pharmacology</i> , 1999, 128, 1419-1426.	2.7	14
252	Effects of Visnagin on Cyclic Nucleotide Phosphodiesterases and Their Role in its Inhibitory Effects on Vascular Smooth Muscle Contraction. <i>General Pharmacology</i> , 1999, 32, 71-74.	0.7	20

#	ARTICLE	IF	CITATIONS
253	Blockade of Cardiac Potassium and Other Channels by Antihistamines. <i>Drug Safety</i> , 1999, 21, 11-18.	1.4	27
254	Role of K ⁺ channel opening and stimulation of cyclic GMP in the vasorelaxant effects of nicorandil in isolated piglet pulmonary and mesenteric arteries: relative efficacy and interactions between both pathways. <i>British Journal of Pharmacology</i> , 1998, 123, 847-854.	2.7	27
255	Effects of propafenone and 5-hydroxy-propafenone on hKv1.5 channels. <i>British Journal of Pharmacology</i> , 1998, 125, 969-978.	2.7	51
256	Structural Determinants of Potency and Stereoselective Block of hKv1.5 Channels Induced by Local Anesthetics. <i>Molecular Pharmacology</i> , 1998, 54, 162-169.	1.0	54
257	Vasoconstrictor and Vasodilator Effects of Disopyramide on Isolated Rat Vascular Smooth Muscle. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 32, 745-752.	0.8	4
258	Effects of Visnadine on Rat Isolated Vascular Smooth Muscles. <i>Planta Medica</i> , 1997, 63, 233-236.	0.7	28
259	Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels. <i>Cardiovascular Research</i> , 1997, 35, 341-350.	1.8	56
260	Effects of Ropivacaine on a Potassium Channel (hKv1.5) Cloned from Human Ventricle. <i>Anesthesiology</i> , 1997, 86, 718-728.	1.3	43
261	Effect of tyrosine kinase and tyrosine phosphatase inhibitors on aortic contraction and induction of nitric oxide synthase. <i>European Journal of Pharmacology</i> , 1997, 338, 25-33.	1.7	23
262	Comparative effects of non-sedating histamine H1 receptor antagonists, ebastine and terfenadine, on human Kv1.5 channels. <i>European Journal of Pharmacology</i> , 1997, 326, 257-263.	1.7	18
263	Endothelium-Derived Nitric Oxide-Dependent Response to Hypoxia in Piglet Intrapulmonary Arteries. <i>Neonatology</i> , 1997, 72, 62-70.	0.9	6
264	Electrophysiological effects of CI-980, a tubulin binding agent, on guinea-pig papillary muscles. <i>British Journal of Pharmacology</i> , 1997, 120, 187-192.	2.7	4
265	Involvement of protein kinase C in reduced relaxant responses to the NO/cyclic GMP pathway in piglet pulmonary arteries contracted by the thromboxane A ₂ -mimetic U46619. <i>British Journal of Pharmacology</i> , 1997, 121, 1323-1333.	2.7	24
266	Effect of descarboethoxyloratadine, the major metabolite of loratadine, on the human cardiac potassium channel Kv1.5. <i>British Journal of Pharmacology</i> , 1997, 122, 796-798.	2.7	16
267	Effects of Several Class I Antiarrhythmic Drugs on Isolated Rat Aortic Vascular Smooth Muscle. <i>General Pharmacology</i> , 1997, 29, 539-543.	0.7	18
268	Molecular Determinants of Stereoselective Bupivacaine Block of hKv1.5 Channels. <i>Circulation Research</i> , 1997, 81, 1053-1064.	2.0	70
269	Stereoselective effects of the enantiomers, quinidine and quinine, on depolarization- and agonist-mediated responses in rat isolated aorta. <i>British Journal of Pharmacology</i> , 1996, 117, 105-110.	2.7	9
270	Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: Sâ€16257â€ and Sâ€16260â€. <i>British Journal of Pharmacology</i> , 1996, 117, 1293-1301.	2.7	26

#	ARTICLE	IF	CITATIONS
271	Effects of Antihypertensive Drugs on Blood Pressure and Metabolic Alterations in the Fructose-Induced Hypertensive Rat. <i>American Journal of Hypertension</i> , 1996, 9, 669-674.	1.0	15
272	Pulmonary versus systemic effects of vasodilator drugs: an in vitro study in isolated intrapulmonary and mesenteric arteries of neonatal piglets. <i>European Journal of Pharmacology</i> , 1996, 314, 91-98.	1.7	6
273	Lack of Endotoxin-Induced Hyporesponsiveness to U46619 in Isolated Neonatal Porcine Pulmonary but Not Mesenteric Arteries. <i>Journal of Vascular Research</i> , 1996, 33, 249-257.	0.6	15
274	Pharmacology of UR-8225, a New Potassium Channel Opener. <i>Cardiovascular Drug Reviews</i> , 1996, 14, 256-271.	4.4	1
275	Class III Antiarrhythmic Effects of Zatebradine. <i>Circulation</i> , 1996, 94, 562-570.	1.6	86
276	Effects of Group B <i>Streptococcus</i> on the Responses to U46619, Endothelin-1, and Noradrenaline in Isolated Pulmonary and Mesenteric Arteries of Piglets. <i>Pediatric Research</i> , 1996, 40, 827-833.	1.1	16
277	Cardiovascular Effects of the Novel Potassium Channel Opener UR-8225. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 26, 295-305.	0.8	12
278	Electromechanical Effects of Zatebradine on Isolated Guinea Pig Cardiac Preparations. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 26, 46-54.	0.8	12
279	Group B <i>Streptococcus</i> and <i>E. coli</i> LPS-induced NO-dependent hyporesponsiveness to noradrenaline in isolated intrapulmonary arteries of neonatal piglets. <i>British Journal of Pharmacology</i> , 1995, 115, 261-266.	2.7	28
280	μ - and δ -opioid receptor-mediated contractile effects on rat aortic vascular smooth muscle. <i>European Journal of Pharmacology</i> , 1995, 277, 99-105.	1.7	38
281	Vasodilator effects of visnagin in isolated rat vascular smooth muscle. <i>European Journal of Pharmacology</i> , 1995, 286, 115-122.	1.7	43
282	Effects of the two enantiomers, S-16257 and S-16260, of a new bradycardic agent on guinea pig isolated cardiac preparations. <i>British Journal of Pharmacology</i> , 1995, 115, 787-794.	2.7	28
283	Stereoselective Block of Cardiac Sodium Channels by Bupivacaine in Guinea Pig Ventricular Myocytes. <i>Circulation</i> , 1995, 92, 3014-3024.	1.6	174
284	Effects of Losartan on Blood Pressure, Metabolic Alterations, and Vascular Reactivity in the Fructose-Induced Hypertensive Rat. <i>Hypertension</i> , 1995, 26, 1074-1078.	1.3	87
285	Propafenone Preferentially Blocks the Rapidly Activating Component of Delayed Rectifier K ⁺ Current in Guinea Pig Ventricular Myocytes. <i>Circulation Research</i> , 1995, 76, 223-235.	2.0	47
286	Effects of lisinopril on cardiac contractility and ionic currents. <i>General Pharmacology</i> , 1994, 25, 825-832.	0.7	5
287	Effects of Oxodipine and Nitrendipine on the Size of Experimental Myocardial Infarct in the Rat. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1994, 74, 321-329.	0.0	9
288	Inhibitory effects of quercetin and staurosporine on phasic contractions in rat vascular smooth muscle. <i>European Journal of Pharmacology</i> , 1994, 262, 149-156.	1.7	27

#	ARTICLE	IF	CITATIONS
289	Class I and III antiarrhythmic actions of prazosin in guinea pig papillary muscles. <i>British Journal of Pharmacology</i> , 1994, 111, 717-722.	2.7	9
290	Voltage- and time-dependent inhibitory effects on rat aortic and porcine coronary artery contraction induced by propafenone and quinidine. <i>British Journal of Pharmacology</i> , 1994, 113, 1281-1288.	2.7	12
291	Vasodilatory effects of flavonoids in rat aortic smooth muscle. Structure-activity relationships. <i>General Pharmacology</i> , 1993, 24, 857-862.	0.7	265
292	Aminophylline preferentially inhibits chloroethylclonidine-insensitive $\hat{\alpha}$ -adrenoceptor-mediated contractions in rat aorta. <i>General Pharmacology</i> , 1993, 24, 1359-1364.	0.7	1
293	Effects of (S)-nafenedone on 45Ca^{2+} fluxes and contractions in rat isolated vascular smooth muscle. <i>European Journal of Pharmacology</i> , 1993, 232, 105-111.	1.7	12
294	Vasodilator effects of quercetin in isolated rat vascular smooth muscle. <i>European Journal of Pharmacology</i> , 1993, 239, 1-7.	1.7	185
295	Effects of lisinopril on electromechanical properties and membrane currents in guinea pig cardiac preparations. <i>British Journal of Pharmacology</i> , 1993, 109, 873-879.	2.7	4
296	Effects of Oleuropeoside in Isolated Guinea-Pig Atria. <i>Planta Medica</i> , 1993, 59, 318-322.	0.7	10
297	Electrophysiological Effects of the Combination of Imipramine and Desipramine in Guinea Pig Papillary Muscles. <i>Journal of Cardiovascular Pharmacology</i> , 1993, 21, 13-20.	0.8	12
298	Vascular Selectivity of Seven Prototype Calcium Antagonists. <i>Journal of Cardiovascular Pharmacology</i> , 1993, 22, 768-775.	0.8	16
299	Propafenone Slows Conduction and Produces a Nonuniform Recovery of Excitability Between Purkinje and Ventricular Muscle Fibers. <i>Journal of Cardiovascular Pharmacology</i> , 1993, 22, 203-207.	0.8	4
300	Electrophysiological effects of CRE-1087 in guinea pig ventricular muscles. <i>British Journal of Pharmacology</i> , 1992, 107, 515-520.	2.7	4
301	Effects of imipramine on the transient outward current in rabbit atrial single cells. <i>British Journal of Pharmacology</i> , 1992, 106, 464-469.	2.7	29
302	Ventricular tachycardia in a patient with congenital coronary arteriovenous fistula. <i>American Heart Journal</i> , 1992, 124, 503-505.	1.2	26
303	Effects of oxodipine on isolated rabbit aorta and mesenteric resistance vessels. <i>European Journal of Pharmacology</i> , 1992, 219, 279-284.	1.7	11
304	Pharmacology of CRE-1087, A New Antiarrhythmic Drug. <i>Cardiovascular Drug Reviews</i> , 1992, 10, 307-322.	4.4	1
305	Effects of aminophylline on contractions and 45Ca uptake in isolated rat vascular smooth muscle. <i>General Pharmacology</i> , 1992, 23, 601-606.	0.7	6
306	Electrophysiological effects of the combination of mexiletine and flecainide in guinea pig ventricular fibres. <i>British Journal of Pharmacology</i> , 1991, 103, 1411-1416.	2.7	6

#	ARTICLE	IF	CITATIONS
307	Effects of propafenone on ⁴⁵ Ca movements and contractile responses in vascular smooth muscle. <i>British Journal of Pharmacology</i> , 1991, 103, 1453-1457.	2.7	13
308	Effects of flecainide on isolated vascular smooth muscles of rat. <i>British Journal of Pharmacology</i> , 1991, 104, 726-730.	2.7	17
309	Mechanisms by which calcium modulates diastolic depolarization in sheep cardiac Purkinje fibers. <i>Journal of Electrocardiology</i> , 1991, 24, 349-361.	0.4	9
310	Effects of (S)-nafnodone, a new antidepressant, in isolated guinea-pig atrial and ventricular muscle fibres. <i>European Journal of Pharmacology</i> , 1991, 199, 43-50.	1.7	13
311	Further characterization of the effects of imipramine on plateau membrane currents in guinea-pig ventricular myocytes. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1991, 344, 645-52.	1.4	31
312	Tonic and frequency-dependent V_{max} block induced by (S)-nafnodone, a new antidepressant drug, in guinea-pig papillary muscles. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1991, 343, 638-44.	1.4	2
313	Tonic and Frequency-Dependent V_{max} Block Induced by Imipramine in Guinea Pig Ventricular Muscle Fibers. <i>Journal of Cardiovascular Pharmacology</i> , 1990, 15, 414-420.	0.8	18
314	Electrophysiologic Interactions Between Mexiletine and Propafenone in Guinea Pig Papillary Muscles. <i>Journal of Cardiovascular Pharmacology</i> , 1989, 14, 351-357.	0.8	15
315	Electrophysiological effects of E-3753, a new antiarrhythmic drug, in guinea-pig ventricular muscle. <i>British Journal of Pharmacology</i> , 1989, 96, 970-976.	2.7	11
316	Evidence of abnormal automaticity and triggering activity in incessant ectopic atrial tachycardia. <i>American Heart Journal</i> , 1988, 116, 550-552.	1.2	10
317	Effect of milrinone on contractility and ⁴⁵ Ca movements in the isolated rabbit aorta. <i>European Journal of Pharmacology</i> , 1988, 148, 239-246.	1.7	25
318	Effect of oxodipine and nifedipine on guinea-pig ileum. <i>General Pharmacology</i> , 1988, 19, 771-774.	0.7	5
319	Tonic and Phasic V_{max} Block Induced by 5-Hydroxypropafenone in Guinea Pig Ventricular Muscles. <i>Journal of Cardiovascular Pharmacology</i> , 1988, 12, 423-431.	0.8	19
320	Electrophysiological Effects of 5-Hydroxypropafenone on Guinea Pig Ventricular Muscle Fibres. <i>Journal of Cardiovascular Pharmacology</i> , 1987, 10, 523-529.	0.8	27
321	Effect of somatostatin on ⁴⁵ Ca fluxes in guinea-pig isolated atria. <i>British Journal of Pharmacology</i> , 1987, 90, 309-314.	2.7	11
322	Electrophysiological effects of propafenone on isolated guinea-pig ventricular muscle and sheep purkinje fibres. <i>European Journal of Pharmacology</i> , 1985, 118, 331-340.	1.7	17
323	Effect of imipramine on calcium and potassium currents in isolated bovine ventricular myocytes. <i>European Journal of Pharmacology</i> , 1985, 108, 121-131.	1.7	54
324	Effects of pinacainide on contractile responses and ⁴⁵ Ca movements in rat isolated vascular smooth muscle. <i>European Journal of Pharmacology</i> , 1985, 111, 227-233.	1.7	4

#	ARTICLE	IF	CITATIONS
325	Effects of bunaphtine on ^{45}Ca movements in rat aortic smooth muscle. <i>Experientia</i> , 1983, 39, 761-763.	1.2	6
326	Comparison of three $\hat{1}^2$ -amino anilides: IQB-M-81, lidocaine and tocanide, on isolated rat atria. <i>European Journal of Pharmacology</i> , 1983, 95, 93-99.	1.7	3
327	A comparison of Josamycin with macrolides and related antibiotics on isolated rat atria. <i>European Journal of Pharmacology</i> , 1982, 80, 285-293.	1.7	25
328	THE MECHANISM OF THE POSITIVE INOTROPIC ACTION OF KETAMINE ON ISOLATED ATRIA OF THE RAT. <i>British Journal of Pharmacology</i> , 1982, 76, 85-93.	2.7	20
329	Electrophysiological effects of bunaphtine on isolated rat atria. <i>European Journal of Pharmacology</i> , 1980, 62, 81-88.	1.7	11
330	ELECTROPHYSIOLOGICAL EFFECTS OF IMPRAMINE ON BOVINE VENTRICULAR MUSCLE AND PURKINJE FIBRES. <i>British Journal of Pharmacology</i> , 1980, 70, 15-23.	2.7	41
331	Electrophysiological effects of desipramine of guinea pig papillary muscles. <i>European Journal of Pharmacology</i> , 1979, 55, 171-179.	1.7	22
332	Interaction of cocaine and bunaphtide on the ^3H -norepinephrine uptake mechanism on isolated left atrium of guinea-pig. <i>Experientia</i> , 1978, 34, 770-770.	1.2	4